For type 2 diabetes mellitus in multiple clinical settings. ANDA 77210, held by Teva Pharmaceuticals USA. Pioglitazone Hydrochloride.
As of Nov 21, 2026, ANDA 77210 (Pioglitazone Hydrochloride), held by Teva Pharmaceuticals USA, was first approved by FDA on Jan 10, 2014, with 3 approved supplements and 0 published complete response letters.
Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. Important Limitations of Use Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease. Pioglitazone tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 10, 2014 | Original application | Approved | None posted |
| Pioglitazone HydrochlorideEQ 15MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 30MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Pioglitazone HydrochlorideEQ 45MG BASE · tablet;oral | Pioglitazone Hydrochloride | Rx |
| Jun 20, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 26, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 26, 2018 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 10, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters